Quotient Limited Reschedules Fourth Quarter and Full Year 2022 Financial Results Announcement to Friday, June 24th and Provides a Preview of Financials
June 21 2022 - 3:56PM
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics
company, today announced that it is rescheduling the release of its
financial results for the fourth quarter and full year 2022 ended
March 31, 2022. The Company will release these financial results
and host a conference call before market open on Friday, June 24,
2022.
Quotient expects to report reagent business
generated product sales of $9.8 million in the fourth quarter of
fiscal 2022 and full fiscal year 2022 revenue of $38.5 million. The
Company recently secured $1.4 million of orders in the first
quarter of fiscal year 2023 for its recently CE Marked Extended
Immunohematology (IH) MosaiQ solution. As of March 31, 2022,
Quotient had $83.2 million in cash and investments and $8.7 million
in restricted cash.
Title: |
Quotient Fourth Quarter and Full Year 2022 Financial Results and
Conference Call |
|
|
|
|
Speakers: |
Manuel O. Méndez, Chief Executive OfficerAli J. Kiboro, Chief
Financial Officer |
|
|
Date: |
Friday, June 24, 2022 |
|
|
Time: |
8:00am ET/ 14:00 CET |
|
|
Conference Call Dial-in Details: |
International: 201-689-8560Switzerland: 0800 835 525United Kingdom:
0800 756 3429US: 877-407-0784Conference ID: 13729874 |
|
|
Webcast: |
Webcast Link - Click HereQuotient Events & Presentations |
The webcast should be accessed 15 minutes prior
to the conference call start time. A replay of the webcast will be
available following the conclusion of the live call and will be
accessible on the Company’s website.
About Quotient Limited
Building on over 30 years of experience in
transfusion diagnostics, Quotient is a commercial-stage diagnostics
company committed to delivering solutions that it believes reshape
the way diagnostics are practiced. MosaiQ, Quotient’s proprietary
multiplex microarray technology, offers the world’s first fully
automated, consolidated testing platform, allowing for multiple
tests across different modalities. MosaiQ is designed to be a
game-changing solution, which Quotient believes will increase
efficiencies, improve clinical practice, deliver significant
workflow improvements, and create operational cost savings to
laboratories around the world. Quotient's operations are based in
Switzerland, Scotland and the US.
The Quotient logo, Quotient MosaiQ and MosaiQ
are registered trademarks or trademarks of Quotient Limited and its
subsidiaries in various jurisdictions.
Forward-Looking Statements
This news release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933 and Section 21E of the Securities Exchange Act of 1934 and
the Private Securities Litigation Reform Act of 1995. These
forward-looking statements may include statements regarding our
expectations of continued growth, the development, regulatory
approval, commercialization and impact of MosaiQ and other new
products (including the potential for using the Company’s MosaiQ
technology to infectious disease diagnostics), current estimates of
upcoming operating results and expectations regarding our future
funding sources. Such statements are based on current assumptions
that involve risks and uncertainties that could cause actual
outcomes and results to differ materially. These risks and
uncertainties, many of which are beyond our control, include delays
or denials of regulatory approvals or clearances for products or
applications; market acceptance of our products; the impact of
competition; the impact of facility expansions and expanded product
development, clinical, sales and marketing activities on operating
expenses; delays or other unforeseen problems with respect to
manufacturing, product development or field trial studies; adverse
results in connection with any ongoing or future legal proceedings;
continued or worsening adverse conditions in the general domestic
and global economic markets, including as a result of the global
COVID-19 pandemic; as well as the other risks set forth in the
Company's filings with the Securities and Exchange Commission.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
Quotient disclaims any obligation to update these forward-looking
statements. The Quotient logo, Quotient MosaiQ and MosaiQ are
registered trademarks or trademarks of Quotient Limited and its
subsidiaries in various jurisdictions.
CONTACT: Investor Relations,
ir@quotientbd.com; +41 22 545 52 26
Quotient (NASDAQ:QTNT)
Historical Stock Chart
From Apr 2024 to May 2024
Quotient (NASDAQ:QTNT)
Historical Stock Chart
From May 2023 to May 2024